OK432-肿瘤疫苗对DBA/2小鼠外周血中T细胞亚群的影响

目的探讨OK432-肿瘤疫苗对小鼠外周血T细胞亚群的影响。方法将36只DBA/2小鼠随机分为OK432-肿瘤疫苗组、OK432组及正常组,每组12只。培养细胞,制作疫苗后,对三组小鼠分别腹腔注射OK432-肿瘤疫苗、OK432及磷酸盐缓冲液（PBS）,每周1次,连续3周。然后分别在1、3、7 d时眼球采血,利用流式细胞术检测外周血中的T细胞亚群的含量,采用SPSS 17.0软件进行数据处理。结果免疫后第3天,OK432-肿瘤疫苗组、正常组、OK432组CD3＋T细胞平均值分别为（55.31±2.06）%、（48.81±3.60）%、（47.21±3.51）%;CD4＋T细胞平均值分别为（40.55±2.32）%、（34.91±1.04）%、（34.24±0.95）%;OK432-肿瘤疫苗组与正常组及OK432组CD3＋、CD4＋T细胞差异均有统计学差异（P〈0.05）。免疫后第7天,OK432-肿瘤疫苗组、正常组CD3＋T细胞平均值分别为（36.26±1.98）%、（23.72±1.90）%;CD4＋T细胞平均值分别为（27.11±0.87）%、（15.42±2.87）%;CD4＋/CD8＋的平均值分别为（3.47±0.33）%、（2.91±0.52）%,差异均有统计学差异（P〈0.05）;OK432-肿瘤疫苗组、OK432组CD8＋T细胞的平均值为（7.85±0.98﹚%、（5.48±0.40）%,两组间差异有统计学意义（P〈0.05）。结论 OK432-肿瘤疫苗能够有效增强小鼠的细胞特异性免疫能力。

Effects of OK432-tumor vaccine on peripheral blood T-lymphocyte subsets of DBA/2 mice

Objective To study the influence of OK432-tumor vaccine on the peripheral blood T cell subsets of mice. Methods 36 DBA/2 mice were randomly divided into the OK432-tumor vaccine group, OK432 group and normal group, each group had 12 cases. After cultured cell and prepared 0K432 tumor vaccines, DBA/2 mice were immunized by OK432-tumor vaccines, OK432 and PBS once a week, for 3 weeks. Then respectively in 1, 3, 7 day blood was picked by remove the eyes of DBA/2 mice. T cell subsets of peripheral blood was tested by flow cytometry, then results were analyzed by SPSS 17.0 software. Results 3 day after immunization, CD3^＋ T cells in the OK432-tumor vaccine group, normal group, 0K432 group were （55.31 ±2.06）%, （48.81±3.60）%, （47.21±3.51）% respectively; C D4^＋ T cells in these groups were （40.55±2.32）%, （34.91±1.1M）%, （34.24_＋0.95）% respectively. The differences of these groups were significant （/9 〈 0.05）. 7 day after immunization, CD3^＋ T cells in OK432-tumor vaccine group and normal group were （36.26±1.98）%,（23.72±1.90）% ;CD4^＋ T cells in these groups were （27.11±0.87）%, （15.42±2.87）% ;CD4^＋/CD8^＋ in these groups were （3.47±0.33）%, （2.9 1±0.52）%; the differences of the two groups were significant （P 〈 0.05）. CD8^＋ T cells in OK432 tumor vaccine group and OK432 group were （7.85±0.98）%, （5.48±0.40）%, the difference of two groups was significant （P 〈 0.05）. Coneluslon OK432-tumor vaccine can effectively enhance the cells specific immune ability in mice.